Big Companies Paying Big Fines

By SHARE

Johnson & Johnson

Next »

3 of 11

« Back

(John Raoux/AP)

The big pharmaceutical firm has reportedly set aside nearly $2 billion to settle charges that it improperly marketed its drug Risperdal for unapproved purposes. The government has cracked down on other firms for promoting such off-label use of their drugs. In May, Abbott Labs agreed to pay a $1.5 billion fine relating to the off-label promotion of Depakote, and last November Merck agreed to pay a $950 million fine related to the improper marketing of Vioxx.

Next: Capital One


You Might Also Like